Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128961 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL128196 | 1.00 | — | — | |
| SCHEMBL1274555 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1275460 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL128011 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL141691 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1228396 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20503206 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20503190 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL126569 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | MIYOSHI OIL & FAT CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| EP-4327889-A1 | FORMULATION USING AMINO ACID AND CARBOXYLIC ACID, ORGANIC SALT, AND COMPOSITION COMPRISING SAME AND USE THEREOF | Miyoshi Oil & Fat Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230340356-A1 | ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY | MIYOSHI OIL & FAT CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-113490710-B | Polycarbonate resin composition | 帝人株式会社 | 2023-05-05 | — | — | CN | disclosed |
| EP-4166635-A1 | ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY | Miyoshi Oil & Fat Co., Ltd. (JP) | 2023-04-19 | — | — | EP | disclosed |
| CN-115702231-A | Additives or compositions for imparting lubricity | 三吉油脂株式会社 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022181381-A1 | ORGANIC AMMONIUM SALT HAVING PHOSPHONATE OR PHOSPHINATE ANION, AND COMPOSITION WHICH IS CAPABLE OF FORMING SAID SALT | ミヨシ油脂株式会社 | 2022-09-01 | — | — | WO | disclosed |
| EP-3082171-B1 | COMPOSITION FOR ANODE BUFFER LAYER OF ORGANIC THIN FILM SOLAR CELL AND ORGANIC THIN FILM SOLAR CELL | NISSAN CHEMICAL CORP (JP) | 2022-04-27 | — | — | EP | disclosed |
| US-20220049092-A1 | POLYCARBONATE RESIN COMPOSITION | TEIJIN LIMITED (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3932981-A1 | POLYCARBONATE RESIN COMPOSITION | Teijin Limited (JP) | 2022-01-05 | — | — | EP | disclosed |
| EP-1239887-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1191008-A1 | COMPOUND HAVING TETRAHYDRONAPHTHALENE SKELETON AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1171162-A2 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6284784-B1 | 2-HYDROXYMETHYL DERIVATIVES | GEORGETOWN UNIVERSITY | 2001-09-04 | — | — | US | disclosed |
| WO-2001028595-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000062808-A2 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1015427-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | disclosed |
| US-5962504-A | ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT | GEORGETOWN UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999012901-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220049092-A1 | POLYCARBONATE RESIN COMPOSITION | SULT1A1, RRS1, RPS24 | CYP1A2 1614/4885CYP2D6 1929/4885MAPT 894/4885 |
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | HAO2, NOTUM, FFAR2 | CYP1A2 1218/4885CYP2D6 1885/4885MAPT 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.